ProCE Banner Series

Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Register now for this interactive, case-based workshop series to effectively personalize the care of patients and learn how to optimally sequence HER2-directed therapies for patients with metastatic breast cancer. After the meeting, download the associated slideset for use in your clinic.

  AAPA
  | ACPE
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended physicians, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with HER2-positive metastatic breast cancer.

All Events

Sequencing Treatment in HER2-Positive Metastatic Breast Cancer [Open Registration]

Past Events

April

30

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

May

21

2024

3:30 PM - 4:30 PM Mountain Time (MT)

Virtual

CCO Simulcast | Host Group NM, Rio Rancho, New Mexico

Faculty

ProCE Banner Faculty
Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

ProCE Banner Faculty
Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

ProCE Banner Faculty
Janice Lu, MD, PhD

Professor and Director of Breast Medical Oncology
Clinical Co-leader, Breast Cancer Research Program
Division of Hematology and Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

ProCE Banner Faculty
Reshma Mahtani, DO

Chief of Breast Medical Oncology
Medical Oncology
Miami Cancer Institute
Miami, Florida

ProCE Banner Faculty
Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

ProCE Banner Faculty
Ruta D. Rao, MD

Professor of Medicine
Medical Director, Rush University Cancer Center
Rush University Medical Center
Chicago, Illinois

ProCE Banner Faculty
Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Topics

Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in the optimal use of HER2-targeted agents for patients with breast cancer.

Target Audience
This educational program is intended for physicians, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with HER2-positive metastatic breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Sequence HER2-directed therapies for breast cancer treatment in accordance with consensus recommendations
  • Gain a deeper understanding of the role of HER2 in breast cancer and the rationale for targeting HER2 with newer agents
  • Manage adverse events associated with newer agents used to treat HER2-positive breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-055-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.